Received Jun 12, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | H3729 | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Unstable Boostrix after temperature excursion administration; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incorrect storage of drug in a 24-year-old female patient who received DTPa (Reduced antigen) (Boostrix) suspension for injection in pre-filled syringe (batch number H3729 with expiry date 29-AUG-2028) for prophylaxis. Co-suspect products included HBV (Engerix B) solution for injection for prophylaxis. On 19-APR-2026, the patient received Boostrix and Engerix B. On an unknown date, an unknown time after receiving Boostrix and Engerix B, the patient experienced incorrect storage of drug (Verbatim: Unstable Boostrix after temperature excursion administration). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt date: 03-JUN-2026 A pharmacist had requested information regarding the administration of 6 vaccines 5 Boostrix and 1 Engerix B that had undergone a temperature excursion, with a maximum temperature of 15.3 degree Celcius for 706 hours, after which the vaccines were considered no longer stable. The batch number was not provided upon follow up with the reporter; Sender's Comments: US-GSK-US2026074273:same reporter